Breakthrough Alzheimer’s Drug Rewires the Brain Instead of Just Clearing Plaques

Researchers at the University of Barcelona developed FLAV-27, an experimental Alzheimer’s compound designed to reset part of the cell’s epigenetic machinery rather than target a single protein.

In animal models, this epigenetic approach appeared to affect multiple hallmarks of the disease at once.

The findings were published in the journal Molecular Therapy.

The study points to epigenetic regulation as a possible new treatment direction for Alzheimer’s.

Approved drugs like lecanemab and donanemab are monoclonal antibodies that clear beta-amyloid plaques, but the study suggests these treatments have limited efficacy, contrasting with the epigenetic strategy.